IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the study No 5, by the Nordic group, 35 newly diagnosed CML patients will receive dasatinib 100 mg/day for 3 months, and then 15 μg/week Peg-IFN.